3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Active not recruiting
2
Withdrawn
1
Unknown
1
Terminated
1
Recruiting
1
Completed
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
5
Breast Neoplasms
3
Prostatic Neoplasms
2
Fallopian Tube Neoplasms
2
Uterine Neoplasms
1
Sarcoma
1
Pancreatic Neoplasms
1
Neoplasm Metastasis
1
Metastatic Hormone-sensitive Prostate Cancer (mHSPC)
1
MMR-D/MSI-H Colorectal Cancers
1
Lymphoma
1
Leiomyosarcoma
1
Glioblastoma
1
Endometrial Neoplasms
1
Cystadenocarcinoma, Serous
1
Colorectal Neoplasms
1
Cholangiocarcinoma
1
Interventions
Temozolomide
9
Magnetic Resonance Spectroscopy
9
Bevacizumab
8
Radiotherapy
4
Radiation
4
Lomustine
3
Carmustine
3
pembrolizumab
2
dexamethasone acetate
2
atezolizumab
2
TIC10 compound
2
Surgical Procedures, Operative
2
Sunitinib
2
Standard of Care
2
Specimen Handling
2
Sorafenib
2
Radiosurgery
2
Irinotecan
2
Dexamethasone
2
Carboplatin
2
Calcium Dobesilate
2
Axitinib
2
Aminolevulinic Acid
2
vocimagene amiretrorepvec
1
tandutinib
1
poly ICLC
1
pazopanib
1
niraparib
1
keyhole-limpet hemocyanin
1
gallium Ga 68 dotatate
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Withdrawn
×
Glioblastoma
×
niraparib
×
Clear all
NCT05666349
2024-03-26
RiNG
University College, London
Phase 1
Withdrawn